Future costs of MS therapy are likely to increase due to new add-on therapy combined with double-digit growth in utilization for existing drugs.
Stacey Ruf, PhD
Advertisement
Articles by Stacey Ruf, PhD
The proportion of Americans diagnosed with Alzheimer's disease (AD) is projected to increase almost 2-fold over the next couple of decades due to size of the Baby Boom generation compared with the total US population.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
GLP-1s and Oncology: The Drug Interaction Clinicians Aren't Talking About
3
The Weekly Dose: Cyclosporiasis Outbreak Grows, AI-Powered Refills Pilot, and New FDA Approvals in Alzheimer Disease, Oncology
4
Improving Detection and Management of ATTR-CM Through Pharmacy Care
5